CD274 and neoplasm: Anti-PD-1/PD-L1 antibodies (e.g., pembrolizumab, nivolumab) work by disrupting the interaction between the inhibitory receptor PD-1, highly expressed on exhausted T cells, Tregs, and other immune cells, and its ligand PD-L1, often upregulated on tumor cells and antigen-presenting cells (Han et al., 2020).